AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $514.09 ($510.72–$516.62, $4.88M total) across 7 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 2, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership, which some investors view as a bearish indicator, though the pre‑arranged plan tempers concerns.

02

Market read

Insider sale news is a standard data point for traders monitoring corporate governance and potential stock pressure.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑01

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency into executive holdings.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

CEO Martine Rothblatt sold $4.9M of United Therapeutics shares via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Potential short‑term downward pressure, likely limited to a few basis points.

Evidence & confidence

A $5M sale by the chairperson is material enough to attract attention, yet the transaction is pre‑arranged and typical for liquidity needs.

Market effects

Sector

May prompt scrutiny of biotech insider activity but unlikely to affect sector broadly.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal; price may remain stable.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary and other diseases.

  • Executive
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min